Attar, E. C., Johnson, J. L., Amrein, P. C., Lozanski, G., Wadleigh, M., DeAngelo, D. J., . . . Larson, R. A. (2013). Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. American Society of Clinical Oncology.
Citação norma ChicagoAttar, Eyal C., et al. Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. American Society of Clinical Oncology, 2013.
MLA CitationAttar, Eyal C., et al. Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. American Society of Clinical Oncology, 2013.